First MENA MAb manufacturer gets EMA GMP certificate

3 September 2018
biosimilars_samples_large

Sponsored content

AryoGen Pharmed has become the first manufacturer of monoclonal antibody (MAb) biologics in the Middle East and North Africa (MENA) region to receive good manufacturing practice (GMP) certification from the European Medicines Agency (EMA).

The Iranian company, which is a member of the CinnaGen Pharmaceutical Group, the biggest biotech enterprise in the MENA region, is focused on manufacturing mAb biosimilars.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars